Preciseley with William Haseltine

“Seasonal Influenza Vaccine Effectiveness, 2021-2022.” Centers for Disease Control and Prevention, December 22, 2022. www.cdc.gov/flu/vaccines-work/2021-2022.html.

Imai Masaki , Ito Mutsumi , Kiso Maki , Yamayoshi Seiya , Uraki Ryuta , Fukushi Shuetsu , Watanabe Shinji , et al. “Efficacy of Antiviral Agents against Omicron Subvariants BQ.1.1 and XBB.” New England Journal of Medicine, 388, no. 1 (2023): 89–91. doi.org/10.1056/nejmc2214302.

Hammond Jennifer , Leister-Tebbe Heidi , Gardner Annie , Abreu Paula , Bao Weihang , Wisemandle Wayne , Baniecki MaryLynn , et al. “Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with COVID-19.” New England Journal of Medicine, 386, no. 15 (2022): 1397–1408. doi.org/10.1056/nejmoa2118542.

Dryden-Peterson Scott , Kim Andy , Kim Arthur Y. , Caniglia Ellen C. , Lennes Inga T. , Patel Rajesh , Gainer Lindsay , et al. “Nirmatrelvir plus Ritonavir for Early COVID-19 in a Large U.S. Health System.” Annals of Internal Medicine, 176, no. 1 (2023): 77–84. doi.org/10.7326/m22-2141.

Ullrich Sven , Ekanayake Kasuni B. , Otting Gottfried , and Nitsche Christoph . “Main Protease Mutants of SARS-COV-2 Variants Remain Susceptible to Nirmatrelvir.” Bioorganic & Medicinal Chemistry Letters, 62 (2022): 128629. doi.org/10.1016/j.bmcl.2022.128629.

Deo Rinki , Choudhary Manish C. , Moser Carlee , Ritz Justin , Daar Eric S. , Wohl David A. , Greninger Alexander L. , et al. “Viral and Symptom Rebound in Untreated COVID-19 Infection,” medRxiv (2022). doi.org/10.1101/2022.08.01.22278278.

Dai Eric Y. , Lee Kannon A. , Nathanson Audrey B. , Leonelli Ariana T. , A. Petros Brittany , Brock-Fisher Taylor , Dobbins Sabrina T. , et al. “Viral Kinetics of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2) Omicron Infection in Mrna-Vaccinated Individuals Treated and Not Treated with Nirmatrelvir-Ritonavir,” medRxiv (2022). doi.org/10.1101/2022.08.04.22278378.

Herper Matthew . “Paxlovid's Failure as a Preventative Measure Raises Questions, but Doctors Still Back It as a Therapeutic.” STAT, May 2, 2022. www.statnews.com/2022/05/02/paxlovid-as-covid-19-prevention/.

“Remdesivir and Three Other Drugs for Hospitalised Patients with COVID-19: Final Results of the Who Solidarity Randomised Trial and Updated Meta-Analyses.” The Lancet, 399, no. 10339 (2022): 1941–53. doi.org/10.1016/s0140-6736(22)00519-0.

Gordon Calvin J. , Tchesnokov Egor P. , Schinazi Raymond F. , and Götte Matthias . “Molnupiravir Promotes SARS-COV-2 Mutagenesis via the RNA Template.” Journal of Biological Chemistry, 297, no. 1 (July 2021): 100770. doi.org/10.1016/j.jbc.2021.100770.

“Merck and Ridgeback's Investigational Oral Antiviral Molnupiravir Reduced the Risk of Hospitalization or Death by Approximately 50 Percent Compared to Placebo for Patients with Mild or Moderate COVID-19 in Positive Interim Analysis of Phase 3 Study.” Merck.com, October 1, 2021. www.merck.com/news/merck-and-ridgebacks-investigational-oral-antiviral-molnupiravir-reduced-the-risk-of-hospitalization-or-death-by-approximately-50-percent-compared-to-placebo-for-patients-with-mild-or-moderat/.

“Merck and Ridgeback Biotherapeutics Provide Update on Results from Move-out Study of Molnupiravir, an Investigational Oral Antiviral Medicine, in at Risk Adults with Mild-to-Moderate COVID-19.” Merck.com, November 26, 2021. www.merck.com/news/merck-and-ridgeback-biotherapeutics-provide-update-on-results-from-move-out-study-of-molnupiravir-an-investigational-oral-antiviral-medicine-in-at-risk-adults-with-mild-to-moderate-covid-19/.

Butler Christopher C , Hobbs F D , Gbinigie Oghenekome A , Rahman Najib M , Hayward Gail , Richards Duncan B , Dorward Jienchi , et al. “Molnupiravir plus Usual Care versus Usual Care Alone as Early Treatment for Adults with COVID-19 at Increased Risk of Adverse Outcomes (PANORAMIC): An Open-Label, Platform-Adaptive Randomised Controlled Trial.” The Lancet (2023) v 401, issue 10373, 281–293,. doi.org/10.1016/s0140-6736(22)02597-1.

Zhou Shuntai , Hill Collin S , Sarkar Sanjay , Tse Longping V , Woodburn Blaide M , Schinazi Raymond F , Sheahan Timothy P , Baric Ralph S , Heise Mark T , and Ronald Swanstrom . “β-D-N4-Hydroxycytidine Inhibits SARS-CoV-2 Through Lethal Mutagenesis But Is Also Mutagenic To Mammalian Cells.” The Journal of Infectious Diseases, 224, no. 3 (2021): 415–19. doi.org/10.1093/infdis/jiab247.

Fountain-Jones Nicholas M. , Vanhaeften Robert , Williamson Jan , Maskell Janelle , Chua I-Ly J , Charleston Michael , and Cooley Louise . “Antiviral Treatments Lead to the Rapid Accrual of Hundreds of SARS-COV-2 Mutations in Immunocompromised Patients.” medRxiv, 2022. doi.org/10.1101/2022.12.21.22283811.

Mukae Hiroshi , Yotsuyanagi Hiroshi , Ohmagari Norio , Doi Yohei , Sakaguchi Hiroki , Sonoyama Takuhiro , Ichihashi Genki , et al. “Efficacy and Safety of Ensitrelvir in Patients with Mild-to-Moderate Coronavirus Disease 2019 (COVID-19): The Phase 2b Part of a Randomized, Placebo-Controlled, Phase 2/3 Study.” Clinical Infectious Diseases, 2022. ciac933 doi.org/10.1093/cid/ciac933.

Tsuji Kohei , Ishii Takahiro , Kobayakawa Takuya , Higashi-Kuwata Nobuyo , Azuma Chika , Nakayama Miyuki , Onishi Takato , et al. “Potent and Biostable Inhibitors of the Main Protease of SARS-COV-2.” iScience, 25, no. 11 (November 1, 2022): 105365. doi.org/10.1016/j.isci.2022.105365.

Xie Yuanchao , Yin Wanchao , Zhang Yumin , Shang Weijuan , Wang Zhen , Luan Xiaodong , Tian Guanghui , et al. “Design and Development of an Oral Remdesivir Derivative VV116 against SARS-COV-2.” Cell Research, 31, no. 11 (2021): 1212–14. doi.org/10.1038/s41422-021-00570-1.

Cao Zhujun , Gao Weiyi , Bao Hong , Feng Haiyan , Mei Shuya , Chen Peizhan , Gao Yueqiu , et al. “VV116 Versus Nirmatrelvir–Ritonavir for Oral Treatment of COVID-19.” New England Journal of Medicine, 2022. doi.org/10.1056/nejmoa2208822.

Zhou Yadi , Liu Yuan , Gupta Shagun , Paramo Mauricio I. , Hou Yuan , Mao Chengsheng , Luo Yuan , et al. “A Comprehensive SARS-COV-2–Human Protein–Protein Interactome Reveals COVID-19 Pathobiology and Potential Host Therapeutic Targets.” Nature Biotechnology, 41, no. 1 (2022): 128–39. doi.org/10.1038/s41587-022-01474-0.

Dang Zhao , Zhu Lei , Xie Lan , Lee Kuo-Hsiung , Malik Faisal , Li Zhijun , Huang Li , and Chen Chin-Ho . “Design and Synthesis of Quinolizidine Derivatives as Influenza Virus and HIV-1 Inhibitors.” Current Medicinal Chemistry, 28, no. 24 (2021): 4995–5003. doi.org/10.2174/0929867328666201229121802.

Huang Li , Zhu Lei , Xie Hua , Goodwin Jeffery Shawn , Rana Tanu , Xie Lan , and Chen Chin-Ho . “Quinolizidines as Novel SARS-COV-2 Entry Inhibitors.” International Journal of Molecular Sciences, 23, no. 17 (2022): 9659. doi.org/10.3390/ijms23179659.

Torchia James A. , Tavares Alexander H. , Carstensen Laura y , Chen Da-Yuan , Huang Jessie , Xiao Tianshu , Mukherjee Sonia , et al. “Optimized ACE2 Decoys Neutralize Antibody-Resistant SARS-COV-2 Variants through Functional Receptor Mimicry and Treat Infection in Vivo.” Science Advances 8, no. 49 (2022). doi.org/10.1126/sciadv.abq6527.

Mao Binli , Thuy Le-Trilling Vu , Wang Kai , Mennerich Denise , Hu Jie , Zhao Zhenyu , Zheng Jiaxin , et al. “Obatoclax Inhibits SARS-COV-2 Entry by Altered Endosomal Acidification and Impaired Cathepsin and Furin Activity in Vitro.” Emerging Microbes & Infections, 11, no. 1 (2022): 483–97. doi.org/10.1080/22221751.2022.2026739.

Cui Zhifen , Zeng Cong , Huang Furong , Yuan Fuwen , Yan Jingyue , Zhao Yue , Zhou Yufan , et al. “CAS13D Knockdown of Lung Protease Ctsl Prevents and Treats SARS-COV-2 Infection.” Nature Chemical Biology, 18, no. 10 (2022): 1056–64. doi.org/10.1038/s41589-022-01094-4.

Hoffmann Markus , Schroeder Simon , Kleine-Weber Hannah , Müller Marcel A. , Drosten Christian , and Pöhlmann Stefan . “NAFAMOSTAT Mesylate Blocks Activation of SARS-COV-2: New Treatment Option for COVID-19.” Antimicrobial Agents and Chemotherapy 64, no. 6 (2020). doi.org/10.1128/aac.00754-20.

Hashimoto Rina , Sakamoto Ayaka , Deguchi Sayaka , Yi Renxing , Sano Emi , Hotta Akitsu , Takahashi Kazutoshi , Yamanaka Shinya , and Takayama Kazuo . “Dual Inhibition of TMPRSS2 and Cathepsin B Prevents SARS-COV-2 Infection in IPS Cells.” Molecular Therapy - Nucleic Acids, 26 (October 19, 2021): 1107–14. doi.org/10.1016/j.omtn.2021.10.016.

Published: Jul 27, 2022. “The Global HIV/AIDS Epidemic.” KFF, September 6, 2022. www.kff.org/global-health-policy/fact-sheet/the-global-hivaids-epidemic/

HIV Undetectable=Untransmittable (U=U), or Treatment as Prevention.” National Institute of Allergy and Infectious Diseases. U.S. Department of Health and Human Services, May 21, 2019. www.niaid.nih.gov/diseases-conditions/treatment-prevention.

Cohen Jon . “Unveiling ‘Warp Speed,’ The White House's America-First Push for a Coronavirus Vaccine.” Science, 2020. doi.org/10.1126/science.abc7056.